Androgen Deprivation Therapy News and Research

RSS
Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

FDA asks manufacturers to add new warnings to labeling of prostate cancer drugs

FDA asks manufacturers to add new warnings to labeling of prostate cancer drugs

Abiraterone Phase III clinical data to be presented at ESMO meeting

Abiraterone Phase III clinical data to be presented at ESMO meeting

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Researchers find radical prostatectomy provides high survival rates

Researchers find radical prostatectomy provides high survival rates

GTx second-quarter net loss increases to $12.9 million

GTx second-quarter net loss increases to $12.9 million

Surgery offers high survival rate for prostate cancer patients: Study

Surgery offers high survival rate for prostate cancer patients: Study

Study finds additional targets for new therapies to treat advanced prostate cancer patients

Study finds additional targets for new therapies to treat advanced prostate cancer patients

GTx reports positive results from toremifene Phase III clinical trial

GTx reports positive results from toremifene Phase III clinical trial

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

FDA issues advisory on prostate cancer drugs

FDA issues advisory on prostate cancer drugs

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen, GTx expand partnership for toremifene 80 mg

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive